T. Rowe Price Associates, Inc. 13D and 13G filings for Turning Point Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-14 2:35 pm Purchase | 2021-12-31 | 13G | Turning Point Therapeutics, Inc. TPTX | T. Rowe Price Associates, Inc. | 3,811,568 7.700% | 1,265,783 (+49.72%) | Filing |
| 2021-02-16 12:24 pm Purchase | 2020-12-31 | 13G | Turning Point Therapeutics, Inc. TPTX | T. Rowe Price Associates, Inc. | 2,545,785 5.200% | 2,545,785 (New Position) | Filing |